Athira Pharma Inc Investors: Company Investigated by the Portnoy Law Firm – GlobeNewswire


Investors can contact the law firm at no cost to learn more about recovering their losses

LOS ANGELES, June 18, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises Athira Pharma Inc (“Athira” or the “Company”) (NASDAQ:ATHA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email:, to discuss their legal rights, or click here to join the case via The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors concerning the Company’s drug candidate ATH-1017. On June 17, 2021, after the market close, the Company reported that it had placed its CEO, Leen Kawas, on temporary leave. Citing “a review of actions stemming from doctoral research” that Kawas conducted while at Washington State University. Bloomberg News reports that while the scientific hypothesis behind Athira came out of the work Kawas did in graduate school, there is risk that whatever comes out of this investigation could have clear negative implications for how investors view the asset, and/or management credibility.

On this news, Athira’s share price fell sharply during intraday trading on April 18, 2021.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar

Attorney Advertising


Please enter your comment!
Please enter your name here